

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**北 斗 嘉 藥 業 股 份 有 限 公 司**  
**BAYTACARE PHARMACEUTICAL CO., LTD.\***

*(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8197)**

**(1) DELAY IN PUBLICATION OF ANNUAL RESULTS  
FOR THE YEAR ENDED 31 DECEMBER 2018**

**AND**

**(2) DATE OF BOARD MEETING**

This announcement is made by Baytacare Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the GEM Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**GEM Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 8 March 2019 and 29 March 2019.

The Board of Directors of the Company wishes to announce that as the auditor of the Company requires more time to perform and complete their audit procedures in respect of the annual results of the Company for the year ended 31 December 2018 (the “**Annual Results**”), the Company expects to publish the Annual Results on 29 April 2019.

The board (the “**Board**”) of directors (the “**Directors**”) of Baytacare Pharmaceutical Co., Ltd\* (the “**Company**”) announces that a meeting of the Board will be held on 29 April 2019 at 4:00 p.m., for the purpose of, among other matters, approving for publication the announcement of the audited annual results of the Company for the year ended 31 December 2018 and considering the payment of a final dividend (if any).

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board  
**Baytacare Pharmaceutical Co., Ltd.\***  
*Executive Director*  
**Cui Bingyan**

Beijing, People's Republic of China, 15 April 2019

*As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Director is Chen Youfang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the website of GEM at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of the publication and the Company’s website at [www.baytacare.com](http://www.baytacare.com) from the date of this announcement.*

*\* for identification purposes only*